Clinical and pharmacoeconomic aspects of the use of prolonged colony-stimulating factors

Febrile neutropenia is one of the frequent complications systemic antitumor therapy, characterized by high rates patient mortality, mortality particularly in patients with pre-existing cardiovascular disease, renal as well presence anemia. In addition, development febrile associated a decrease dose intensity chemotherapy, which also has an adverse effect on long-term results treatment number malignant tumors. This dictates need for widespread use preventive measures aimed at minimizing risk FN cancer receiving cytotoxic chemotherapy. Numerous studies have shown that prophylactic granulocyte colony-stimulating factors can significantly reduce duration profound neutropenia, incidence and - most importantly related mortality. article devoted to review modern approaches (G-CSF) context current system care financing clinical statistical groups (CSGs) territory Russian Federation. Various aspects drugs this class prevent its primary secondary prevention, rules G-CSF use, data effectiveness feasibility different scenarios are considered detail. The advantages long-acting dosage forms their place practice considered.